TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - MODERNA | Market Closed - Boerse Frankfurt Warrants 15:49:27 2024-06-28 EDT | ||
| 4.09 EUR | +7.07% |
|
| Current month | +122.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 4.1 | +7.33% |
| 24-06-27 | 3.82 | +3.80% |
| 24-06-26 | 3.68 | +51.44% |
| 24-06-25 | 2.43 | -1.22% |
| 24-06-24 | 2.46 | -8.55% |
Real-time Boerse Frankfurt Warrants
Last update June 28, 2024 at 03:49 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SW61BP |
| ISIN | DE000SW61BP9 |
| Date issued | 2024-05-28 |
| Strike | 161.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.1 € |
|---|---|
| Lowest since issue | 0.27 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Certificates
- Certificat
